Document is current
Any future updates will be listed below
-
Authors
Tabar, V. https://orcid.org/0000-0002-1284-1670
Sarva, H.
Lozano, A. M.
Fasano, A. https://orcid.org/0000-0001-5346-0180
Kalia, S. K.
Yu, K. K. H. https://orcid.org/0000-0002-2394-4990
Brennan, C.
Ma, Y. https://orcid.org/0000-0002-8383-6748
Peng, S. https://orcid.org/0000-0003-0653-636X
Eidelberg, D. https://orcid.org/0000-0002-0854-864X
Tomishima, M.
Irion, S.
Stemple, W.
Abid, N.
Lampron, A.
Studer, L. https://orcid.org/0000-0003-0741-7987
Henchcliffe, C.
- License Information
-
More Information
Article History
Received: 26 July 2024
Accepted: 26 February 2025
First Online: 16 April 2025
Competing interests
: V.T. is a scientific advisor and receives research support from BlueRock Therapeutics. H.S. has done consulting work for Novo Nordisk, BlueRock Therapeutics, Neurocrine and Neuroderm; and has also received clinical trial support from BlueRock Therapeutics, Prevail Therapeutics, Neuroderm, Sun Pharma, Meira GTX, Bukwang, Insightec, Biogen, Genentech, Cerevance, UCB and National Institutes of Health (NIH). A.M.L. has done consulting work for Medtronic, Abbott, Boston Scientific and Insightec; and is a scientific officer of Functional Neuromodulation. A.F. has stock ownership in Inbrain Pharma and has received payments as consultant and/or speaker from AbbVie, Abbott, Boston Scientific, CereGate, Dompé Farmaceutici, Inbrain Neuroelectronics, Ipsen, Medtronic, Iota, Syneos Health, Merz, Sunovion, Paladin Labs and UCB; and has received research support from AbbVie, BlueRock Therapeutics, Boston Scientific, Medtronic, Praxis and ES, and receives royalties from Springer. S.K.K. has received consultant fees, support and/or speaker honoraria from Novo Nordisk, Abbott, Boston Scientific and Medtronic. Y.M. has served as a consultant, study investigator and site principal investigator to acquire and/or analyse PET/SPECT and MRI brain images in multicentre clinical trials of stem cell and gene therapies for PD; and has received research support and paid travel from BlueRock Therapeutics and Aspen Neuroscience, research support from AskBio and MeiraGTx, and paid consulting services from Novo Nordisk. S.I., M.T., N.A. and W.S. are employees of BlueRock Therapeutics. A.L. is currently an employee of Dompé. L.S. is a scientific advisor and receives research support from BlueRock Therapeutics and is a scientific co-founder of DaCapo Brainscience. C.H. has received honoraria for consulting from Abbvie, AskBio and Certara; stock options for scientific advisory board participation from Axent Biosciences; honoraria for scientific advisory board participation from Bayer, Canary Health Technologies and ProJenX; honoraria for DSMB meetings from MeiraGTx; research support from BlueRock Therapeutics and Weston Brain Institute; and honoraria for presentations from the American Academy of Neurology, ASGCT and the Parkinson Study Group. The other authors declare no competing interests.
